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Research in context 
 
Evidence before this study. 
Successive systematic reviews performed by the International Working Group of the Diabetic 
Foot and others  have failed to show consistent cost effective benefit of any topical therapy to 
accelerate healing of foot ulcers in patients with diabetes and the majority of published 
studies have significant methodological weaknesses. Nevertheless, a number of studies have 
suggested the potential benefit of blood-derived products even though the results have 
hitherto been inconsistent.  
 
Added value of this study 
This study is, to our knowledge, the first large randomised observer blind controlled trial of 
the use of multi-layered patches comprising autologous leucocytes, platelets and fibrin 
generated by the bedside and without adding any reagents. The effect of the patches was 
compared with good usual care in people with diabetic foot ulcers which were not healing 
despite good usual care. The study was conducted to a high standard as recommended in 
recent guidelines.  
In the intention-to-treat analysis the addition of the autologous multi-layer patch to usual 
good standard care was associated with a significant 1.58 fold increase in the proportion of 
wounds confirmed healed. There were no significant differences in the number of adverse  
events, in particular the number of patients who developed anaemia.  
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Implications of all the available evidence  
In people with diabetes complicated by foot ulcers which are not healing despite best 
standard of care, this new bedside treatment has the potential to significantly accelerate 
wound healing. 
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Abstract  
 
Background: The LeucoPatch® device uses bedside centrifugation without additional reagents 
to generate a disc comprising autologous leucocytes, platelets and fibrin which is applied to 
the surface of the wound. The aim of the study was to test the effectiveness of LeucoPatch on 
the healing of hard-to-heal foot ulcers in people with diabetes. 
Methods: This was a multicentre, international, observer-blind, randomised controlled trial of 595 people with diabetes and a foot ulcer who consented to participate. After a 4 
week run-in-period those with a reduction in ulcer area of < 50% were randomised to either 
pre-specified good standard care alone or care supplemented by weekly application of 
LeucoPatch. The primary outcome was percentage of ulcers healed within 20 weeks, defined 
as complete epithelialisation confirmed by an observer blind to randomisation group and 
maintained for four weeks. 
Findings: 269 people were randomised; mean age 62 years, 82% male and 83% Type 2 
diabetes. In the intervention group 34·1% (n=45/132) of ulcers healed within 20 weeks vs. 
21·6% (n=29/134) of the controls (OR 1·58, 95% CI 1·06 - 2·35; p= 0·0235) by intention-to-
treat analysis. Time to healing was shorter in the intervention group (p=0·0246). No 
difference in adverse events was seen between groups.  
Interpretation: The use of LeucoPatch is associated with significant enhancement of healing 
of hard-to heal foot ulcers in people with diabetes.  
Funding The study was funded by Reapplix ApS, Birkerød, Denmark. The funder had no role 
in study design or study performance.  
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Trial registration: International Standard Randomised Controlled Trial, ISRCTN 27665670. 
ClinicalTrials.gov, NCT02224742. Registered on 5 July 2013.  
 
Background 
 
Diabetic foot ulcers (DFUs) are common and present a major source of disability, distress and cost. 
Healing is often delayed for many months and limb loss through amputation is common. The 
incidence of new ulceration after healing is approximately 40% at 12 months and DFUs therefore 
present a major financial cost to patients, their families and health care services.1,2 A principal cause 
of the problem is the absence of treatments for which there is evidence of effectiveness and this 
relates to a large extent to the quality of available research, which is mostly of poor design.3  
It follows that trials to document the effectiveness of treatments for this complex clinical problem 
should conform to defined criteria for trial design and reporting.4 To that end, it is necessary that the 
evaluation of any treatment should be undertaken in a population which has already been shown to be 
responding poorly to good standard care ( ie. ‘hard to heal’ ulcers) and should be based on a 
comparison of the effect of the treatment being tested with contemporaneous controls in an 
appropriately blinded randomised trial.   
 
One possible treatment option for non-healing ulcers is the use of platelet-rich plasma or platelet-rich 
fibrin, which may promote healing in DFUs judged to be ‘hard to heal’ through the release of 
cytokines and growth factors involved in tissue repair, angiogenesis and inflammation.3,5-8   While the 
use of platelet preparations is not new, it has been associated with only inconsistent evidence of 
benefit 3,9,10. However, the recent development of the capacity to produce multi-layered patches 
comprising autologous leucocytes, platelets and fibrin by the bedside and without adding any reagents 
(Leucopatch, Reapplix ApS, Birkerød, Denmark) (Figure1) has introduced a possible new option. 
11,12 Two pilot studies, of which one included participants with hard-to heal diabetic foot ulcers only, 
have reported beneficial effects on ulcer healing, without raising any safety issues.13,14 
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We now report the outcome of a randomised controlled observer-blinded trial aimed to determine 
whether the application of LeucoPatch, when used in addition to usual care in a multidisciplinary 
specialist diabetes foot clinic setting, is superior to usual care alone in healing of hard-to heal DFUs 
which are not infected at the time of randomisation.  
 
Methods 
Trial Design 
The trial protocol and rationale has previously been published.15 This was a multicentre, 
multinational, observer-blind, randomised controlled trial, undertaken in 32 centres with specialist 
diabetic foot clinics in the UK, Denmark, and Sweden.  After providing written informed consent, all 
participants were entered into a 4 week run-in period before randomisation 1:1 to either the 
intervention plus usual care arm or usual care alone arm. The intervention period of 20 weeks was 
followed by a 6 week observation period. The study was performed in compliance with the regulatory 
requirements of the three countries, in accordance with the ethical principles of the Declaration of 
Helsinki and recommendations for Good Clinical Practice. The study was approved by the National 
Research Ethics Committee West Midlands - Birmingham South (reference 13/WM/0202) and by the 
R&D departments of the participating NHS trusts (UK), the ethics committee for Region Midtjylland, 
Committee 1, Denmark (Reference 1-10-72-99-13) (Denmark) and by the Regionala 
Etikprovningsnamnden,  Lund, Sweden (Reference 2013/6). This trial is registered with 
Clinicaltrials.gov (NCT02224742) and ISRCTN 27665670. 
 
Study setting and participants 
Participants were people aged 18 years and over who had diabetes according to WHO criteria 
complicated by one or more foot ulcers and a baseline HbA1c of  ≤108 mmol/mol. Ulcers were 
situated below the level of the malleoli, but excluded ulcers confined solely to the interdigital clefts 
because of  the difficulty in measurement and in placing a patch directly on the wound. All ulcers 
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were “hard to heal” meaning that the cross-sectional area decreased by less than 50%, and the cross-
sectional area of the index ulcer was  ≥50 and ≤1000 mm2 at the end of the 4 week run-in period.16,17 
At baseline, the index ulcer was clinically non-infected according to the criteria of the Infectious 
Diseases Society of America (IDSA)18 and either the ankle-brachial index (ABPI) of the affected limb 
was between 0·50 and 1·40 or the dorsalis pedis pulse and/or the tibialis posterior pulse was palpable. 
Participants had to have the capacity to understand study procedures, and to provide written informed 
consent.  
Participants were not eligible for inclusion if any of the following applied: cross-sectional area of the 
index ulcer had increased by ≥25% or had decreased by >50% during the 4 week run-in period, or 
was either smaller than 50 mm2 or larger than 1000 mm2 at the end of that time. They were similarly 
ineligible if there were clinical signs of infection of the index ulcer or other reason to suspect that 
infection was present at randomisation, if a revascularisation procedure in the affected limb was 
planned, or had been undertaken within the 4 weeks prior to the baseline visit,  if the foot ulcer had 
been treated with growth factors, stem cells or an equivalent preparation within the 8 weeks prior to 
the baseline visit or if there was a need for continued use of negative pressure wound therapy. 
Participants were also not eligible if their haemoglobin concentration was <105 g/L at screening, they 
had sickle-cell anaemia, haemophilia, thrombocytopenia (<100x109/L) or any other clinically 
significant blood dyscrasia, if there was known potential infectivity of blood products, including 
known HIV and hepatitis, if they were on renal dialysis or had an estimated GFR (based on cystatin C 
or serum creatinine) of  <20 ml/min/1·73m2, if they were on current treatment with cytotoxic drugs or 
with systemically administered glucocorticoids or other immunosuppressants, if they were unlikely to 
comply with the need for weekly visits because of other planned activity, if they had been in another 
interventional clinical foot ulcer-healing trial within the 4 weeks prior to the baseline visit, if they had 
been previously randomised to the current study or if the investigator judged that they did not have 
the capacity to understand the study procedures or provide written informed consent. 
Patients were recruited from and were managed in one of 32 specialist diabetic foot clinics in 3 
countries (UK, Denmark, Sweden). 
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Randomisation and blinding  
Participants who were eligible following the run-in period, were randomly assigned to either usual 
care plus intervention or usual care alone. The computer-generated, web based, randomisation code 
using permuted blocks of randomly varying size (2, 4 and 6) was created by the Nottingham Clinical 
Trials Unit (CTU). Trial participants were allocated with equal probability to each treatment arm with 
stratification by centre, and by ulcer area ≤100mm2 versus >100mm2. 
Clinical investigators assessing outcomes were masked to group assignment throughout the study 
duration, as was the study statistician before the clinical database had been cleaned and 
locked. Participants, care givers and site investigators were not blind to the treatment allocation. In the 
event of a disagreement between site investigators and the blinded clinical primary outcome assessor, 
or if a blinded assessment was not done or was delayed beyond the permitted window described in the 
protocol, a blinded adjudication committee reviewed the digital images. 
 
Procedures 
Clinical investigators were instructed to manage all eligible ulcers with the best available standard of 
usual care, including offloading, according to International Working Group of the Diabetic Foot 
(IWGDF) guidelines either alone (during the run-in period and those in the control arm) or in addition 
to the intervention (during the 20 week active treatment phase if in the intervention arm).21 Basic 
demographics, medical history and eligibility criteria were assessed at baseline. Thereafter, 
assessment of wound characteristics, wound size by acetate tracing (area assessed at a later date using 
Image J20 by a single blinded assessor), digital images of the ulcer taken post debridement, active 
medication including antibiotic prescriptions, type of offloading used (classified into 9 types), adverse 
device effects, serious adverse events and adverse device events were recorded at every visit. 
Participant visits were scheduled every 2 weeks during the run-in period, and weekly during the 
intervention period. Should the index ulcer have healed during the intervention period, the 
participants were seen again at 2 weeks and 4 weeks post healing, with a blinded assessment of 
healing both at the point of healing and at the 4 weeks post healing visit. A detailed description of 
study procedures is provided in the previously published protocol paper.15 
9 
 
 
The study intervention 
The active intervention was the application of a LeucoPatch patch directly to the wound which was 
performed at the bed-side in the clinical centres. Each week a patch was produced by drawing 18 mL 
of the patient’s venous blood into a LeucoPatch device (Reapplix ApS, Birkerød, Denmark), which 
was then transferred to a LeucoPatch Centrifuge (Reapplix Aps; Birkerød, Denmark) and spun for 20 
minutes according to an automatic and pre-specified programme. The final three layered LeucoPatch 
(Figure 1) was then removed from the device using aseptic precautions, cut into appropriate size if 
necessary, and applied onto the ulcer with the leucocyte side adjacent to the surface of the ulcer, 
before being covered by a low adherent, knitted viscose rayon primary dressing (Tricotex®, Smith & 
Nephew, London, UK) and a protective secondary dressing. Participants with an ulcer area larger than 
5 cm2 had two patches prepared and applied. New patches were made and applied on a weekly basis 
until healing or the end of the study.  
 
Outcomes 
The primary outcome was the number (%) of ulcers that healed within 20 weeks following 
randomisation. Healing was assessed following any necessary debridement and was defined as 
complete epithelialisation without drainage, and which was maintained for four weeks. Healing was 
confirmed both at the start and the end of the four week period by an appropriately trained observer 
who was blind to randomisation group. The date of healing was defined as that at which the ulcer was 
first noted by the clinical researcher and confirmed by an observer who was blind to the 
randomisation group.  
 
Secondary ulcer-related outcomes included time to healing in those that healed within the 20 week 
active intervention period, the proportion of healed ulcers at 12 and 26 weeks, the change in ulcer area 
at 4, 12, 16, 20 and 26 weeks (as compared to week 0), was assessed from digital images of acetate 
tracings using Image J,20 the incidence of secondary infection, the number of days of systemic 
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antibiotic therapy administered for infection of the foot ulcer during the 20 weeks from 
randomisation. Secondary patient-related outcomes also included the incidence of major (above 
ankle) amputation affecting the target limb by 12, 20 and 26 weeks, the incidence of major 
amputation affecting the contralateral limb by 26 weeks, the incidence of minor (below ankle) 
amputation affecting the target limb by 12, 20 and 26 weeks, the incidence of minor amputation 
affecting the contralateral limb by 26 weeks, and incidence of new anaemia, defined as haemoglobin 
level below <105 g/L (6.5 mmol/L) and decreased more than 10 % compared to baseline. 
 
Statistical analysis 
Previous non-controlled LeucoPatch outcome data suggested a healing rate (intention to treat) of 54% 
during a 20 week follow-up period, in a cohort of patients selected by a less than 40 % ulcer area 
reduction during a 2 week run-in-period.14 The incidence of healing in a matched control group as 
well as in placebo/control groups in other diabetic foot studies with inclusion and exclusion criteria 
similar to those used in the present study was between 27 and 32% at 20 weeks follow-up, although 
some authors have reported healing rates below 10%.3 A sample size for comparing two proportions 
with Fleiss continuity correction, based on alpha = 0·05 and beta = 80% and with an incidence of 
healing in the control group of 30% and with an improvement of 18 percentage points (i.e. to 48%) in 
the treatment group gave a sample size of 250 evaluable patients. To allow for 30% drop out a sample 
size of 350 randomised participants was estimated.  A pre-planned interim analysis of the primary 
endpoint was carried out by an independent statistician, not otherwise involved in the study, when 140 
patients had completed 20 week follow-up. The purpose was to check for non-futility, establish the 
drop-out rates and, if necessary, recalculate the sample size. The result of the interim analysis was 
only conveyed to the independent Data Monitoring Committee (DMC). On the advice of the DMC the 
Trial Steering Committee (TSC) suggested an adjustment to the sample size to from 350 to 260 
patients based on fewer drop outs than anticipated, and further, on the basis of a slight imbalance in 
the numbers randomised to each group, to 269. The interim analysis meant that the level of 
significance, for the primary endpoint, was reduced to 0·04. 
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Statistical analyses were conducted with SAS EG 7.1. All analyses were performed on both the 
intention-to-treat (ITT) population and the per-protocol (PP) populations. The ITT population 
included all randomised patients from whom any post randomisation data were collected. The PP 
population included all ITT patients without major protocol deviations and who were treated with the 
allocated dressing for at least four weeks, was used for a confirmatory sensitivity analysis. Safety 
endpoints were analysed using the safety population which consisted of all randomised patients. The 
difference between the two populations  amounted to 3 patients who were randomised, but never had 
a followup visit.  
The primary analysis was carried out by a Chi-square test, as well as by logistic regression with 
healed/not healed as outcome and treatment and other explanatory variable. Pertinent variables, such 
as wound area at baseline, ulcer depth, duration of wound, APBI and country, were included 
exploratively, but only wound size at baseline and duration of wound (less than, or more than 1 year) 
ended up as a covariates.  
 
Time (measured in days) to healing was analysed by regression analysis of survival data based on the 
Cox proportional hazards model, with a censor variable indicating whether the subject was healed or 
not. A graphical illustration is presented with Kaplan-Meier curves.  
All other proportions were analysed by Chi-square tests, except where the low numbers, necessitated 
the use of Fishers Exact test (e.g. amputations, AEs and SAEs). Total number of days of antibiotic 
therapy was analysed by a t-test and pain reduction was analysed by repeated measures 
analysis.   
A p-value <0·05 was considered as statistically significant in all other analyses except the Primary 
Endpoint analysis. 
 
Role of the funders and sponsor  
The study was sponsored by Nottingham University Hospitals NHS Trust, Nottingham UK, and was 
funded by Reapplix ApS, Birkerød, Denmark. The funder had no role in study design, study 
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performance, data collection, data analyses, data interpretation, or writing of the report. The 
statistician (JJ) had full access to all data in the study. The chief investigators (FG, WJ, LT, ML) had 
full access to all data after the database was locked and had final responsibility for the decision to 
submit the results for publication.   
 
Results 
The first patient was consented in August 2013 and the last in May 2017. Altogether 595 people with 
diabetes were consented and 269 randomised, 55% of participants failed run-in, the main reason for 
this being change in ulcer area of more than 50% over 4 weeks (Figure 2). 137 participants were 
randomised to usual care and 132 participants to LeucoPatch in addition to usual care, of these 134 
and 132, respectively were included in the ITT-population. Patients were recruited from 32 specialist 
centres; 22 in the UK, 3 in Sweden and 7 in Denmark. The mean number of patients consented was 
18·5 (range 1- 78), and the mean number of patients randomised 8·4 (range 0-31) per centre.  
The baseline characteristics were well balanced between treatment groups (Table 1). The mean age of 
participants was 61·9 (SD 1·6) years, 81·6 % male, and  83·5 % had Type 2 diabetes. The median 
duration of diabetes was 16 (IQR 10-23) years and the median HbA1c 66 (IQR 55-77) mmol/mol. The 
majority of index limbs were neuropathic with 85·3 % of participants being unable to feel a 10-g 
monofilament at ≥ 2 out of 3 pre-specified sites on the affected foot. The majority of ulcers were 
greater than 100 mm2 (74·4%) and superficial (86·5 %). Only 9 ulcers (3·4 %) extended to bone. The 
majority of the ulcers were situated on the forefoot (77·8 %). The 2 groups were well matched in 
terms of the types of offloading used throughout the study. 
 
Within 20 weeks 45 (34 %) of index ulcers in the LeucoPatch group had healed vs. 29 (22 %) in the 
usual care group (p=0·029) giving an unadjusted odds-ratio of 1·58 (96% CI 1·04 - 2·40, p=0·024) 
for healing in the ITT population. On 6 occasions the decision that an ulcer had healed was made by 
the blinded assessment committee on the basis of the digital images. On each occasion the committee 
agreed that the ulcer was healed. In the PP population, healing within 20 weeks was 44 (39%) in the 
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intervention group vs 28 (26%) in the usual care group (OR 1·47 (96% CI 0·98 -2·23, p=0·049). 
Healing incidence at 12 and 26 weeks is shown in Table 2. The median time to healing in those who 
healed was 72 (IQR 56-103) days in the LeucoPatch group vs. 84 (IQR 64-98) days in the usual care 
group (Figure 3)(p=0·0343). The change in ulcer area from baseline is given in Figure 4. 
 
Diabetic foot infection occurred in 51 participants in the LeucoPatch group and 63 in the usual care 
group (p=0·21). No differences in minor or major amputations between groups could be seen after 12, 
20 or 26 weeks (Table 2). No difference in change of pain score between the groups could be 
identified during the follow-up period (Table 2). 
 
The incidence of new anaemia was not significantly different between groups (9·8 % vs. 8·2 %). 
Overall there were no differences in adverse events between groups (Table 2). 
The country of recruitment did not significantly affect the results.  
 
Discussion 
 
This multicentre, observer-blinded, randomised controlled trial found a significantly higher incidence 
of healing within 20 weeks (unadjusted OR 1·58) in those receiving LeucoPatch applications for hard 
to heal DFUs when compared to good quality standard care. There was also a significantly higher rate 
of decrease in ulcer area in the intervention group as well as a reduced time to healing in those that 
healed. There was no difference in the incidence of either major or minor amputation and none in the 
incidence of any adverse events or serious adverse events. In particular, there was no increased 
incidence of anaemia in the intervention group – even in those with reduced GFR – despite the need 
for weekly venesection. There was also no significant difference between groups in the incidence of 
either the number of episodes of clinical infection or of antibiotic use, even though a difference may 
have been expected because of the leucocytes contained within the application.  
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The main strength of the study was that the design and conduct of this study fulfilled the exacting 
requirements specified for work in this field.4 The study population was appropriate in that it was 
designed to focus on those with hard-to-heal ulcers – which is the group for which new treatments are 
most needed. All investigators were instructed to manage participants according to the principles of  
good standard care using pre-specified criteria and this was reinforced at regular investigator 
meetings. The groups were well-matched. Recruitment was to target and retention was very high, with 
few drop-outs.  
 
The main weakness regarding study design and conduct was that it was not possible to blind either the 
participant or the clinical researcher. The use of sham venepuncture was rejected as being unethical, 
but assessment of the primary outcome was undertaken by an independent and blinded observer and 
backed up with digital imaging. The recruited population was representative of a  hard to heal 
population and this is reflected in the low overall incidence of healing in the non-intervention group. 
Nevertheless, an element of selection is evident in that the mean age was slightly less than anticipated 
(approximately 62 years as opposed to the expected 67 years) and presumably reflects the need for 
participants to attend each week for up to 5 months. There was also a high proportion of males 
(approximately 82% instead of the expected 67%) but this is now recognised as being a typical feature 
of large trials in this field. The overall incidence of healing was lower than anticipated, and lower than 
that observed in the pilot studies, but is likely to reflect the more rigid selection of a defined hard-to-
heal population. It is also possible that the low healing rate reflected a poor standard of usual care, and 
this this might have been different between the 2 groups. We feel that this is unlikely as the low 
healing rate in those already preselected as being “hard to heal” following a 4 week run-in period was 
similar to that seen in the series of Coerper et al.17 Additionally the 2 groups were well matched in 
terms of their baseline characteristics, their offloading strategies, and similar numbers were 
revascularised during the 26 week follow-up, and so we feel that a differential standard of care is not 
the explanation for the additional benefit seen on healing in the intervention group.  
It is of interest that the odds ratio for healing in the intervention group was, however, very similar to 
that which was the basis of the sample size calculation, being 1·58. It is acknowledged that the 
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number of patients screened who were not eligible may suggest that the patient population was not 
representative of patients seen in a specialist diabetic foot clinic. We felt that for this protocol, 
although we were including hard to heal ulcers, we had to exclude those with little chance of healing 
within the 20 weeks of the study (for example very large ulcers, those with severe ischaemia, and 
those with severe renal disease) as their data had little chance to contribute to the final results. The 
median number of ulcers consented per centre was, however, similar to or even slightly higher than a 
recently published RCT of another product designed to accelerate wound healing in patients with 
neuro-ischaemia.21 
 
Thus, this study has demonstrated the apparent effectiveness of this new intervention in the 
management of people with hard to heal DFUs. It adds to the increasing number of studies that have 
reported benefit from the use of platelets and platelet-derived application to the surface of the chronic 
wound. Such benefit could be mediated through any of a number of mechanisms relating to the 
process of inflammation and tissue repair. But in addition to delivering living, autologous platelets to 
the wound surface, LeucoPatch also delivers living autologous neutrophils and macrophages and 
could, therefore, confer additional advantages. Even so, no difference was observed between groups 
in the apparent incidence of episodes of wound infection.  
 
The production of LeucoPatch patches is simple and quick and easily undertaken during the course of 
routine clinical practice. Weekly application was used for this definitive study. It is of interest, 
however, that the analysis of the PP population, ie those who attended and/or had LeucoPatch 
treatment on a weekly basis for most of the required visits resulted until healing, showed a similar 
improvement in healing at 20 weeks. It is possible, therefore, that the treatment may not need 
continuing until full healing and could be discontinued earlier even though this possibility has not 
been tested with this protocol. It is also possible that LeucoPatch will be effective in other types of 
DFU (including those that are not so hard to heal) but this has also not been assessed in this study. 
Whilst not directly tested in this study the low numbers of drop outs from the study protocol suggests 
that patients find this an acceptable treatment strategy.  
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Whereas reviews of the published literature on wound care products for DFUs have repeatedly 
emphasised the urgent need for trials of better quality, this is the third relatively robust RCT to be 
reported in the last 12 months: the others being a study of a dressing product which has an action on 
the activity of matrix metalloproteinases (sucrose octasulphate dressing)21 and a dressing which 
releases intradermal nitrix oxide (ProNox1).22 While these three approaches represent contrasting 
modes of action, and include different types of ulcer with different durations and different healing 
criteria, all three trials reported an almost identical figure for unadjusted OR: approximately 1·5 - 1·6.   
 
In summary, this trial demonstrates a clinical and statistically significant benefit associated with the 
use of weekly application if autologous immune cell/fibrin/platelet patches (LeucoPatch) in a 
population of people with hard-to-heal diabetic foot ulcers.  The treatment was without apparent 
adverse event, specifically without evidence of new onset anaemia. It is possible that this treatment 
might also be of benefit in other types of DFU but this has not been studied.  
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LEGENDS 
 
Table 1. Baseline clinical characteristics  
Data are given as median (IQR) or number of participants (%). 
 
Table 2. Primary secondary and safety study outcomes 
Data are given for important primary and secondary outcomes for patients allocated to intention-to-treat 
population in people randomised to usual care alone (N=134) or usual care and Leucopatch  plus usual care 
(N=132). For the pre protocol analyses the population was usual care alone (N=107) and Leucopatch plus usual 
care (N=114). 
   
Figure 1. Schematic of a LeucoPatch showing the 3 layers 
 
Figure 2. Consort Diagram 
 
Figure 3. Time to healing 
Kaplan-Meyer survival curve showing proportion of ulcers remaining unhealed, with healing defined as 
complete epithelialisation without any drainage sustained for at least 4 weeks, in the intention-to-treat 
population in people randomised to usual care alone (134) or usual care and Leucopatch (132).  
 
Figure 4. Ulcer area reduction 
 
